Top 5 Infectious Disease New Stories Week of March 15-March 22 Contagionlive.com Newfound bacterial compound kills fungi that are resistant to multiple antifungals Fierce Biotech Source link
Gilead’s Once Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study Moupali Das, MD, MPH, presented results from a Phase 1 study of two once-yearly intramuscular (IM) formulations of lenacapavir for HIV pre-exposure prophylaxis (PrEP). Both formulations demonstrated strong pharmacokinetic profiles, with lenacapavir concentrations sustained above the 95% effective threshold for … Read more
Under a magnification of 9560X, this digitally-colorized scanning electron microscopic (SEM) image depicted numerous clumps of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. Image credit: CDC/ Janice Haney Carr/ Jeff Hageman, MHS In a new 10-year analysis, the CDC found antimicrobial resistance in hospitals declined from 2012 to 2019, but rose again during the acute COVID-19 pandemic … Read more
At CROI 2025, Kellie Hawkins, MD, assistant professor of medicine at the University of Colorado and attending infectious disease physician at Denver Health, discussed findings from the RECOVER Program, which explores the impact of HIV on Long COVID. The study examined the incidence of Long COVID in people living with HIV (PWH) and aimed to … Read more
Archyde Candida auris: Navigating Diagnostic Challenges in Healthcare Table of Contents 1. Candida auris: Navigating Diagnostic Challenges in Healthcare 2. Evaluating Diagnostic Techniques 3. Culture-Based Methods: Strengths and Weaknesses 4. Molecular Diagnostics: High Sensitivity and Specificity 5. Clinical Implications and Practical Considerations 6. Unanswered Questions and Future Directions 7. Moving Forward with Confidence 8. What … Read more
Koos Korsten, MD, PhD, MSc Image credits: LinkedIn Candidozyma auris (Candida auris) is an emerging, potentially multi-drug-resistant pathogen that presents a significant challenge in healthcare settings, particularly in intensive care units and hospital environments. Accurate and timely detection of C auris is crucial for infection control, especially during outbreaks. In this study, researchers compared the … Read more
Five All-Oral Regimens Show Efficacy in the Phase 3 endTB Trial for Rifampin-Resistant TB A Phase 3 trial has shown that five all-oral regimens, administered over 9 months, are as effective as the standard 18-24 month treatment for fluoroquinolone-susceptible, rifampin-resistant tuberculosis (RR-TB). The trial demonstrated that four of the regimens, including combinations of bedaquiline, clofazimine, … Read more
Bavarian Nordic is a vaccine company focused on developing and manufacturing vaccines for infectious diseases. Bavarian Nordic received approval from the US Food and Drug Administration (FDA) for its Vimkunya chikungunya vaccine for individuals aged 12 and older. The vaccine, the first virus-like particle (VLP) single-dose vaccine for chikungunya, was approved based on phase 3 … Read more
GSK is a biopharma company focused on developing medicines and vaccines to address health challenges. GSK plc announced that the US Food and Drug Administration (FDA) has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for individuals aged 10 through 25 years. This vaccine is designed to protect against five major serogroups … Read more
Bavarian Nordic is a vaccine company focused on developing and manufacturing vaccines for infectious diseases. Bavarian Nordic received approval from the US Food and Drug Administration (FDA) for its Vimkunya chikungunya vaccine for individuals aged 12 and older. The vaccine, the first virus-like particle (VLP) single-dose vaccine for chikungunya, was approved based on phase 3 … Read more